Research funder · United States
Alzheimer's Drug Discovery Foundation
Nonprofit organization
- Grants since 2016
- 326
- Awarded, last 5 years (where amounts are published)
- $245.1M
- Funded works, last 5 years
- 1 178
- Funded works, all time
- 2 272
Grants
2026–2028 · research · Drug Discovery
Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-BRAIN)
Randall Bateman · Washington University in St. Louis
2026–2027 · research · Drug Discovery
Novel ASO therapeutics to rebalance 3R/4R tau isoforms for frontotemporal dementia and other tauopathies
Chaolin Zhang · Columbia University Irving Medical Center
2026–2027 · research · Biomarkers
“The development and evaluation of a clinical RT-QuIC test for diagnosis of TDP-43 linked Fronto-temporal dementias: A small multicentre trial.”
Neil Mckenzie · University of Edinburgh
2026–2027 · research · Biomarkers
Longitudinal Study with Positron Emission Tomography Using [¹⁸F]PI-2620 in Primary Tauopathies
Alexis Moscoso · Biogen (United States)
2026–2027 · research · Diagnostics Accelerator
Proteomic Characterization of the Bluefield Cohort
Farhad Imam · Alzheimer's Disease Data Initiative (addi)
2026–2027 · research · Diagnostics Accelerator
Novel Measures of Neuroinflammation in Alzheimer's disease
Jeffrey Dage · Indiana University
2026–2028 · research · Drug Discovery
Small Molecule Prevention of Alzheimer’s Disease
Thomas Leyh · Albert Einstein College of Medicine
2026–2028 · research · Drug Discovery
Developing a novel, conditionally activated siRNA (CASi) molecule for treatment of Alzheimer’s Disease
Anindya Bhattacharya · Switch Therapeutics
2026–2027 · research · Clinical
MITI-101, a novel antibody therapeutic to treat Alzheimer's disease and related disorders
Leonid Gorelik · Mindimmune Therapeutics, Inc.
2026–2027 · research · Drug Discovery
Optimizing a Gene-Targeted Therapeutic to Enhance TBK1 Expression in Genetic FTD
Timothy Miller · Washington University in St. Louis
2026 · prize · Drug Discovery
2026 Annual Goodes Prize for Excellence in Alzheimer's Drug Discovery
Randall Bateman · Washington University in St. Louis
2026–2029 · research · Clinical
Clinical Phase 2 Proof-of-Concept Study Evaluating the Effect of ALX-001 on Biomarkers of Synapse Structure and Function.
Timothy Siegert · Allyx Therapeutics
2026–2028 · research · Clinical
A Randomized phase 1b trial to evaluate the therapeutic efficacy of septin glue REM392 in mild-to-moderate AD patients.
Gerard Griffioen · Remynd
2026 · research · Clinical
ASPIRE.FTD: A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Graeme Fielder · Aviadobio
2026–2027 · research · Prevention
Long-term follow-up of the Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT)
Kristine Yaffe · University of California, San Francisco
2026–2027 · research · Biomarkers
Development of a Scalable CSF YWHAG:NPTX2 ELISA Assay for Cognitive Prognosis in Early AD
Alison Goate · Icahn School of Medicine at Mount Sinai
2025–2029 · research · Diagnostics Accelerator
Integration of the neotiv digital cognitive assessments in the Swedish REAL AD study to screen and monitor preclinical Alzheimer’s disease
David Berron · Neotiv Gmbh
2025–2026 · research · Diagnostics Accelerator
The Global Neurodegeneration Proteomics Consortium: V2 expansion for ADNI and other key AD datasets
Farhad Imam · Alzheimer's Disease Data Initiative (addi)
2025–2028 · research · Diagnostics Accelerator
Diagnostics Accelerator Speech & Language Consortium: Harmonized Repository for the Exploration of Speech and Language Biomarkers for Neurodegenerative Disease
Felicia Goldstein · Emory University
2025–2026 · research · Biomarkers
Develop a diagnostic biomarker for frontotemporal dementia.
Philip Wong · Johns Hopkins University
2025–2027 · research · Diagnostics Accelerator
Determining %p-tau217 and MTBR-243 by immunoassay
Nicholas Ashton · Banner Health
2025–2026 · research · Clinical
Open-label multiple dosing study in asymptomatic GRN-Frontotemporal dementia patients to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VES001.
Mads Fuglsang Kjølby · Vesper Bio Aps
2025–2028 · research · Biomarkers
Alzheimer’s Disease Blood-Based Biosignature for Predicting Clinical Progression
Tatiana Lagos · Foundation For The National Institutes Of Health, Inc.
2025–2026 · research · Biomarkers
Assessing the diagnostic and prognostic value of perivascular spaces imaging in cognitive impairment and dementia through a novel fully-automated robust algorithm
Giuseppe Barisano · Board Of Trustees Of The Leland Stanford Junior University
2025–2026 · research · Drug Discovery
Novel prolyl oligopeptidase ligands to target Tau in frontotemporal dementia and other tauopathies
Timo Myöhänen · Polku Therapeutics
2025–2029 · research · Diagnostics Accelerator
Diagnostics Accelerator Speech & Language Consortium: Harmonized Repository for the Exploration of Speech and Language Biomarkers for Neurodegenerative Disease
Yael Bensoussan · University Of South Florida Research Foundation
2025–2027 · research · Drug Discovery
Defining oligonucleotide therapeutics that reverse FUS proteinopathy
James Shorter · University of Pennsylvania
2025–2027 · research · Drug Discovery
Development of a granulin biologic to treat progranulin deficient FTD.
Thomas Kukar · Emory University
2025–2026 · research · Diagnostics Accelerator
Integrating cfRNA and Proteomics with AI for Next-Generation Alzheimer’s Diagnostics
Bojk Berghuis · Superfluid Dx
2025–2027 · research · Drug Discovery
Development of novel CCR3 chemokine receptor peptide and small molecule functionally selective biased antagonists to treat neuroinflammation in Alzheimer’s disease.
Steven Ackerman · University of Illinois Chicago
2025–2028 · research · Diagnostics Accelerator
Quality control (QC) program for CSF and plasma biomarkers for Alzheimer’s disease
Henrik Zetterberg · University of Gothenburg
2025–2027 · research · Drug Discovery
AAV-mediated clearance of tau aggregates in vivo
Marc Diamond · The University of Texas Southwestern Medical Center
2025–2027 · research · Drug Discovery
A new therapeutic antibody for Frontotemporal Dementia
Chenxi Qiu · Beth Israel Deaconess Medical Center
2025–2026 · research · Diagnostics Accelerator
Scientific validation of a digital MoCA for use in the general practice
Ziad Nasreddine · Moca Cognition
2025–2026 · research · Biomarkers
Development of new PET radiotracers for detecting and tracking innate immune activation in the whole body and CNS of Alzheimer's disease
Michelle James · Board Of Trustees Of The Leland Stanford Junior University
2025–2027 · research · Diagnostics Accelerator
A novel, accurate plasma proteomic assay for screening and diagnosis of individuals with Alzheimer’s Disease and Alzheimer’s Disease Related Dementia (AD/ADRD)
Nicholas Seyfried · Emtherapro
2025–2028 · research · Diagnostics Accelerator
Development of ARGO DX™ for a new generation of blood-based diagnostics for Alzheimer’s disease and related neurodegenerative diseases
Xiao-Jun · Alamar Biosciences
2025–2028 · research · Diagnostics Accelerator
Diagnostics Accelerator Speech & Language Consortium: Harmonized Repository for the Exploration of Speech and Language Biomarkers for Neurodegenerative Disease
Andrew Saykin · Indiana University
2025–2027 · research · Prevention
Leveraging a large scale randomized clinical trial to determine whether statins can prevent Alzheimer’s Disease neuropathology and dementia
Joanne Ryan · Monash University
2025–2026 · research · Diagnostics Accelerator
Alzheimer’s disease specificity and sensitivity analyses of circRNA blood biomarkers
Nikolaos Mellios · Circular Genomics Inc